Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
The two faces of neuromyelitis optica.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
BTG plc Close Period Update
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
The interplay between the intestinal microbiota and the brain.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Tcelna® (imilecleucel-T)

Pages